Hero MotoCorp Expands Pact With Harley-Davidson To Launch New Motorcycle And X440 Variants
Hero MotoCorp Ltd. has extended its partnership with Harley-Davidson Motor Co. to "expand the Harley-Davidson X440 into new variants" as well as to develop a new motorcycle.
The scope of the partnership includes "development of new motorcycle and contract-based manufacturing", according to an exchange filing on Friday.
Harley-Davidson X440, one of the key offerings of Harley-Davidson, is manufactured at Hero MotoCorp's Garden Factory at Neemrana, Rajasthan.
This collaboration marked both the company's entry into the 440cc segment for the first time in India.
The motorcycle was launched in India in July 2023 at an ex-showroom introductory price range of Rs 2.29 lakh to 2.69 lakh. In the subsequent month, the prices were raised by Rs 10,500 across all variants.
Q2 Performance
Hero MotoCorp's revenue rose 10.8% year-on-year to Rs 10,463 crore for the second quarter of the current fiscal 2025.
The company recorded a net profit of Rs 1,204 crore, indicating a 14.2% year-on-year growth for the July- September quarter of the ongoing fiscal.
The motorcycle and scooter manufacturer's earnings before tax, interest, depreciation and amortisation surged to Rs 1,516 crore, up 14.1% year-on-year for the three months ended Sept. 30, 2024 while its margins rose by 40 basis points to 14.5% in the same period.
Shares of Hero MotoCorp closed 0.87% lower at 4,237.95 per share on the National Stock Exchange. In contrast, the benchmark Nifty 50 rose 0.27%. The stock has risen 4.27% in last 12 months and 2.94% on a year-to-date basis.
Out of the 44 analysts monitoring the company, 30 have a 'buy' rating on the stock, and seven maintain 'hold' and seven recommend 'sell', according to Bloomberg data. The average of 12-month analysts' price targets suggests a potential upside of 25%.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.